Gene expression profiling in the myelodysplastic syndromes

Hematology

Volumn 10, Issue 4, 2005, Pages 281-287

  Pellagatti, Andrea ^a   Fidler, Carrie ^a   Wainscoat, James S ^a   Boultwood, Jacqueline ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acute myeloid leukemia; Expression profiling; Microarrays; Myelodysplastic syndromes

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALPHA THALASSEMIA; ARTICLE; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

BONE MARROW; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HUMANS; MYELODYSPLASTIC SYNDROMES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 29144511153     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330500065680     Document Type: Article

References (60)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-1660.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Ann Oncol 1999;10:1419-1432, Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
5. Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001;14:479-495.
6. Johansson B, Mertens F, Mitelman F. Cytogenetic deletion maps of hematologic neoplasms: Circumstantial evidence for tumor suppressor loci. Genes Chromosomes Cancer 1993;8:205-218.
7. Boultwood J, Fidler C. Chromosomal deletions in myelodysplasia. Leuk Lymphoma 1995;17:71-78.
8. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M, Yamane Y, Inazawa J, Abe T, Kashima K. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994;8:1331-1336.
9. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 1994;8:638-641.
10. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996;33:127-138.
11. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990.
12. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 2001; 73:429-437.
13. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998;58:5009-5013.
14. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson Jr., JR, Elkahloun AG. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999;59:5656-5661.
15. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999;286:531-537.
16. Gibbons RJ, Pellagatti A, Garrick D, Wood WG, Malik N, Ayyub H, Langford C, Boultwood J, Wainscoat JS, Higgs DR. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet 2003;34:446-449.
17. Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, Kaneko T, Mori M, Kirito K, Toshima M, Nakamura Y, Saito K, Kano Y, Furusawa S, Ozawa K, Mano H. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001;98:422-427.
18. Liang R, Fei YJ, Prasad PD, Ramamoorthy S, Han H, Yang-Feng TL, Hediger MA, Ganapathy V, Leibach FH. Human intestinal H + /peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem 1995;270:6456-6463.
19. Liu W, Liang R, Ramamoorthy S, Fei YJ, Ganapathy ME, Hediger MA, Ganapathy V, Leibach FH. Molecular cloning of PEPT 2, a new member of the H + /peptide cotransporter family, from human kidney. Biochim Biophys Acta 1995; 1235:461-466.
20. Shimamoto K, Lebrun B, Yasuda-Kamatani Y, Sakaitani M, Shigeri Y, Yumoto N, Nakajima T. DL-threo-beta-benzyl-oxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol 1998;53:195-201.
21. Simonin F, Befort K, Gaveriaux-Ruff C, Matthes H, Nappey V, Lannes B, Micheletti G, Kieffer B. The human delta-opioid receptor: Genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol Pharmacol 1994;46:1015-1021.
22. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-1271.
23. Laborda J, Sausville EA, Hoffman T, Notario V. dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J Biol Chem 1993;268:3817-3820.
24. Sato K, Mano H, Ariyama T, Inazawa J, Yazaki Y, Hirai H. Molecular cloning and analysis of the human Tec protein-tyrosine kinase. Leukemia 1994;8:1663-1672.
25. Harnick DJ, Jayaraman T, Ma Y, Mulieri P, Go LO, Marks AR. The human type 1 inositol 1,4,5-trisphosphate receptor from T lymphocytes. Structure, localization, and tyrosine phosphorylation. J Biol Chem 1995;270:2833-2840.
26. Moore KA, Pytowski B, Witte L, Hicklin D, Lemischka IR. Hematopoietic activity of a stromal cell transmembrane protein containing epidermal growth factor-like repeat motifs. Proc Natl Acad Sci USA 1997;94:4011-4016.
27. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002;100:3553-3560.
28. Ueda M, Ota J, Yamashita Y, Choi YL, Ohki R, Wada T, Koinuma K, Kano Y, Ozawa K, Mano H. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 2003;123:288-296.
29. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000;19:2638-2644.
30. Gross M, Liu B, Tan J, French FS, Carey M, Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001;20: 3880-3887.
31. Nelson V, Davis GE, Maxwell SA. A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. Apoptosis 2001;6:221-234.
32. Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev 2001;15:3088-3103.
33. Liu B, Shuai K. Induction of apoptosis by protein inhibitor of activated Stat1 through c-Jun NH2-terminal kinase activation. J Biol Chem 2001;276:36624-36631.
34. Oshima Y, Ueda M, Yamashita Y, Choi YL, Ota J, Ueno S, Ohki R, Koinuma K, Wada T, Ozawa K, Fujimura A, Mano H. DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia. Leukemia 2003;17:1990-1997.
35. Valkov NI, Sullivan DM. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 1997;34:48-62.
36. Tsutsumi C, Ueda M, Miyazaki Y, Yamashita Y, Choi YL, Ota J, Kaneda R, Koinuma K, Fujiwara S, Kisanuki H, Ishikawa M, Ozawa K, Tomonaga M, Mano H. DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia. Exp Hematol 2004;32:828-835.
37. Jinnai I, Tomonaga M, Kuriyama K, Matsuo T, Nonaka H, Amenomori T, Yoshida Y, Kusano M, Tagawa M, Ichimaru M. Dysmegakaryocytopoiesis in acute leukaemias: Its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy. Br J Haematol 1987;66:467-472.
38. Brito-Babapulle F, Catovsky D, Galton DA. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 1987;66:445-450.
39. Maserati E, Aprili F, Vinante F, Locatelli F, Amendola G, Zatterale A, Milone G, Minelli A, Bernardi F, Lo Curto F, Pasquali F. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer 2002;33:93-97.
40. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, Prieto F, Granada I, Hernandez JM, Cigudosa JC, Diez JL, Bureo E, Marques ML, Arranz E, Rios R, Martinez Climent JA, Vallespi T, Florensa L, Woessner S. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000;108:346-356.
41. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): A perspective and review highlighting current controversies. Leuk Res 2003;27:95-120.
42. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002;99:3129-3135.
43. Paulsson K, Sall T, Fioretos T, Mitelman F, Johansson B. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 2001;130:160-165.
44. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, Sloand EM, Young NS. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004;.
45. Pellagatti A, Esoof N, Watkins F, Langford CF, Vetrie D, Campbell LJ, Fidler C, Cavenagh JD, Eagleton H, Gordon P, Woodcock B, Pushkaran B, Kwan M, Wainscoat JS, Boultwood J. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Haematol 2004;125:576-583.
46. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 2003; 189:117-128.
47. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996;114:107-132.
48. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000;60:3305-3312.
49. Di Bacco A, Gill G. The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor. Oncogene 2003;22:5436-5445.
50. Fosslien E. Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31:325-348.
51. Higgs DR, Vickers MA, Wilkie AO, Pretorius IM, Jarman AP, Weatherall DJ. A review of the molecular genetics of the human alpha-globin gene cluster. Blood 1989;73: 1081-1104.
52. Higgs DR, Bowden DK. Clinical and laboratory features of α-thalassemia syndromes. In: Nagel RL, editor. Disorders of hemoglobin. Cambridge: Cambridge University Press; 2001. p 431-469.
53. Higgs DR, Wood WG, Barton C, Weatherall DJ. Clinical features and molecular analysis of acquired hemoglobin H disease. Am J Med 1983;75:181-191.
54. Weatherall DJ, Old J, Longley J, Wood WG, Clegg JB, Pollock A, Lewis MJ. Acquired haemoglobin H disease in leukemia: Pathophysiology and molecular basis. Br J Haematol 1978;38:305-322.
55. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell 1995;80:837-845.
56. Gibbons RJ, Higgs DR. Molecular-clinical spectrum of the ATR-X syndrome. Am J Med Genet 2000; 97:204-212.
57. Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004;103:2019-2026.
58. Szaniszlo P, Wang N, Sinha M, Reece LM, Van Hook JW, Luxon BA, Leary JF. Getting the right cells to the array: Gene expression microarray analysis of cell mixtures and sorted cells. Cytometry A 2004;59:191-202.
59. Grate LR. Many accurate small-discriminatory feature subsets exist in microarray transcript data: Biomarker discovery. BMC Bioinformatics 2005;6:97.
60. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002; 99:12963-12968.